Henry Ford Health enrolled the first US patients in a global clinical trial evaluating pulmonary artery denervation for pulmonary hypertension linked to heart disease. The start of US enrollment expands access to the device-based strategy in a population where progression can still lead to right heart failure. The trial’s broader significance is that it positions denervation as a potential escalation step when medical therapy is insufficient—while also providing a path to generate US data that align with international study protocols. For cardiopulmonary researchers and device companies, the milestone also signals continued momentum for interventional trials designed to translate hemodynamic modulation into measurable clinical endpoints.